Magunguna masu tasowa suna amfani da su da yawa daga dukkanin shekaru daban-daban, ciki har da yara. Magungunan maganin masu tasowa suna da tasiri don maganin cututtukan dermatitis (eczema), ƙananan kwayoyin cututtuka (ciki har da rashes da gubar gishiri da masarawa suka haifar da su), siffofin daji na fata, da kuma sauran mawuyacin gaske , ciki har da cizon kwari .
Duk da haka, masu maganin steroid na saman zasu iya samun sakamako mai dorewa, musamman tare da yin amfani da juyayi masu girma.
Sabili da haka, lokacin da ake amfani da steroid a saman yara, dole ne a yi amfani da sifofin ƙananan aiki a duk lokacin da zai yiwu don rage girman sakamakon.
Firayi masu tasowa wanda FDA ta amince
Sai dai wasu nau'o'in maganin maganin ƙwayoyin cuta ne kawai da Cibiyar Abinci da Drugurma ta Amurka (FDA) ta amince da ita don amfani da yara. Duk waɗannan, banda hydrocortisone , suna samuwa ne kawai ta takardar sayan magani. Wadannan sun hada da, da aka jera domin karfin ƙarfin hali (mafi rauni ga karfi):
- Over-the-Counter Cortizone / Cortaid (hydrocortisone) kashi 0.5 da kashi 1 bisa dari da kuma maganin shafawa, an yarda da yara a matsayin matashi masu shekaru biyu.
- Derma-Smoothe (fluocinolone) kashi 0.01 bisa dari man fetur, an yarda da yara a matsayin matashi na tsawon shekaru uku.
- Dama / Verdeso (kashi 0.05 bisa dari gel / kumfa, an yarda da yara a matsayin matashi a matsayin watanni 3.
- Dermatop (prednicarbate) 0.1 bisa dari kirim, yarda ga yara a matsayin matasa a matsayin shekara 1.
- Cutivate (fluticasone propionate) kashi 0.05 bisa dari, an yarda da yara a matsayin matashi a matsayin watanni 3.
- Elocon (mometasone) 0.1 bisa dari da kuma maganin maganin shafawa, an yarda da yara a matsayin matashi masu shekaru biyu.
Yayinda sauran masu amfani da kwayoyin surar da yawa suna da yawa kuma an ba da izini ga yara ƙanana, irin su triamcinolone, dole ne a fahimci cewa wadannan kwayoyin sitik din suna da kariya kadan lokacin da aka yi amfani dashi a cikin yara, saboda haka an dauke su "daga FDA".
Ƙara koyo game da alamun cututtuka a cikin yara .
Damuwa da Tsaro ga 'yan kwayoyin Steroids da Yara
Magungunan maganin magungunan maganganu suna kawar da asalin hypothalamic-pituitary-adrenal (HPA). Wannan dakatar da kyawawan kwayoyin halittar kwayoyin halitta zai iya haifar da ciwo na Cushing , da jini mai tsanani, da kuma yaduwar glucose a cikin fitsari. Yara suna fuskantar hatsari fiye da tsofaffi kuma suna iya nuna rashin hana ci gaba, jinkirta karuwar kayan aiki, da kuma ƙara matsa lamba cikin kwakwalwa. Duk da yake rahotanni game da waɗannan abubuwa saboda cututtuka masu tasowa masu ban mamaki suna da wuya, akwai lokuta guda biyu a cikin shekaru 50 da suka wuce kuma wasu mutuwar yara.
A sakamakon haka, sassan masana sunyi jinkirin amincewa da sayen steroid din na sayar da su a kan-da-counter. Suna tsoron cewa iyaye ba za su fahimci hadarin ba yayin da suke sayen kwayoyi su yi amfani da su a gida. Duk da yake a mafi yawancin lokuta sakamakon cututtukan steroid a kan HPA axis yana nufin kawai ƙananan yana cikin ƙananan haɗari, idan sun fuskanci yanayin ilimin likita na jiki (maimakon jin dadi) irin su cututtuka, tiyata, ko ƙwayar cuta mai tsanani, zasu iya samun barazanar rayuwa rikitarwa. Hanyoyin da ke kan tasirin HPA sun kasance masu juyayi kuma yawanci sukan dawo cikin al'ada cikin makonni.
Kalma Daga
Tsarin ƙasa shine zalunta masu maganin steroid din tare da girmamawa da amfani da su kamar yadda aka tsara kuma kawai kamar yadda shawararka ta likita da likitan ka.
Akwai wasu zaɓuɓɓuka don amfani da yaronka. Amfani da mafi ƙasƙanci na steroids masu mahimmanci yana da mahimmanci don kula da yanayin, kuma kawai amfani da shi don tsawon lokaci da shawarar, sune ainihin kayan tsaro. Kada kayi amfani da steroid wanda aka ba da takarda ga wani mutum a kan yaro.
> Sources:
> Dhar S, Seth J, Parikh D. Tsarin Tsarin Tsarin Kwayoyin Tsarin Corticosteroids. Littafin Indiya na Labaran Halitta . 2014; 59 (5): 460. Doi: 10.4103 / 0019-5154.139874.
> Saraswat A. Topical Corticosteroid Yi Amfani da Yara: Hanyoyin Cutar da Yadda Za a Rage su. Indian J Dermatol Venereol Leprol 2010; 76: 225-8.